Multivalent PD-1/PD-L1 Binding Constructs for Checkpoint Bridging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cancer treatments struggle to effectively counteract immune evasion mechanisms employed by tumors, leading to inadequate immune response against malignancies.
Innovation Solution
Development of multispecific and multivalent constructs targeting both PD-1 and PD-L1, which block the interaction between PD-1 expressed by immune cells and its ligands while bridging immune cells or tumor cells, enhancing T cell proliferation, IFNγ production, and cytolytic activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If combinations of individual antibodies are used to target PD-1 and PD-L1, then the immune response is enhanced, but the anti-tumor efficacy is insufficient compared to multispecific constructs
Solution Approach 1:
The patent merges multiple antibody functions into a single multispecific construct that simultaneously targets both PD-1 and PD-L1. This construct contains multiple binding sites that can engage both the receptor and ligand in a single molecular entity, thereby improving anti-tumor efficacy while maintaining a unified therapeutic agent rather than requiring complex combinations of separate antibodies
Solution Approach 2:
The multispecific construct serves multiple functions simultaneously: it blocks the PD-1/PD-L1 interaction to prevent immune evasion, bridges tumor cells and immune cells to enhance activation, and can engage multiple targets (PD-1 and PD-L1) with a single agent. This multi-functionality resolves the contradiction by providing comprehensive anti-tumor activity without requiring multiple separate therapeutic components
2Adaptability or versatility
If stoichiometric combinations of individual antibodies are used, then both PD-1 and PD-L1 can be targeted, but the treatment requires multiple agents increasing complexity
Solution Approach 1:
The patent combines the targeting capabilities for both PD-1 and PD-L1 into a single multispecific antibody construct. This unified agent contains binding sites for both targets, eliminating the need to administer multiple separate antibodies in stoichiometric ratios while maintaining the ability to engage both receptors and ligands simultaneously
Solution Approach 2:
The multispecific construct functions as a universal agent that can target multiple checkpoints (PD-1 and PD-L1) with a single molecular entity. This resolves the contradiction by providing versatile targeting capability through one agent rather than requiring multiple specialized antibodies
3Reliability
If PD-1/PD-L1 interaction is blocked without bridging, then immune evasion is counteracted, but T cell activation and proliferation are not sufficiently enhanced
Solution Approach 1:
The multisspecific construct acts as an intermediary that performs dual functions: it blocks the harmful PD-1/PD-L1 interaction while simultaneously serving as a bridge to physically connect tumor cells and immune cells. This bridging function enhances T cell activation and proliferation beyond what simple blockade achieves, resolving the contradiction by adding functional complexity that improves immune response
4Ease of manufacture
If individual antibodies are used separately, then manufacturing is simpler, but the therapeutic potency is reduced compared to multispecific constructs
Solution Approach 1:
The patent merges multiple antibody specificities into a single manufactured product. While the molecular structure is more complex, the manufacturing process produces one unified therapeutic agent rather than requiring precise mixing and stabilization of multiple separate antibodies, thereby maintaining manufacturing feasibility while achieving superior therapeutic potency through simultaneous multi-target engagement
Data Source
AI summary
The present disclosure relates to compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression. In some embodiments, provided herein are compositions that block the interaction between PD-1 and its ligand (e.g., PD-1 and/or PD-L2) while promoting the interaction of the cells on which PD-1 and its ligand are expressed. Also provided are methods of using such compositions.